AU2006287160B2 - 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists - Google Patents

6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists Download PDF

Info

Publication number
AU2006287160B2
AU2006287160B2 AU2006287160A AU2006287160A AU2006287160B2 AU 2006287160 B2 AU2006287160 B2 AU 2006287160B2 AU 2006287160 A AU2006287160 A AU 2006287160A AU 2006287160 A AU2006287160 A AU 2006287160A AU 2006287160 B2 AU2006287160 B2 AU 2006287160B2
Authority
AU
Australia
Prior art keywords
alkyl
substituents
optionally substituted
fluoro
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006287160A
Other languages
English (en)
Other versions
AU2006287160A1 (en
Inventor
John Gordon Allen
Karin Briner
Anne Marie Camp
Manuel Javier Cases-Thomas
Richard Charles Hoying
Maria Angeles Martinez-Grau
Michael Philip Mazanetz
Natalia Pokrovskaia
Richard Edmund Rathmell
Roger Ryan Rothhaar
Selma Sapmaz
Andrew Caerwyn Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2006287160A1 publication Critical patent/AU2006287160A1/en
Application granted granted Critical
Publication of AU2006287160B2 publication Critical patent/AU2006287160B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2006287160A 2005-09-01 2006-09-01 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists Ceased AU2006287160B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71358405P 2005-09-01 2005-09-01
US60/713,584 2005-09-01
PCT/US2006/034430 WO2007028131A1 (fr) 2005-09-01 2006-09-01 2,3,4,5-TÉTRAHYDRO-1H-BENZO[d]AZÉPINES SUBSTITUÉS EN POSITION 6 EN TANT QU’AGONISTES DU RÉCEPTEUR DE 5-HT2C

Publications (2)

Publication Number Publication Date
AU2006287160A1 AU2006287160A1 (en) 2007-03-08
AU2006287160B2 true AU2006287160B2 (en) 2012-04-05

Family

ID=37499390

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006287160A Ceased AU2006287160B2 (en) 2005-09-01 2006-09-01 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists

Country Status (17)

Country Link
US (1) US8420631B2 (fr)
EP (1) EP1926712B1 (fr)
JP (1) JP5237810B2 (fr)
CN (1) CN101253153A (fr)
AT (1) ATE437859T1 (fr)
AU (1) AU2006287160B2 (fr)
BR (1) BRPI0615033A2 (fr)
CA (1) CA2619287C (fr)
CY (1) CY1110486T1 (fr)
DE (1) DE602006008155D1 (fr)
DK (1) DK1926712T3 (fr)
ES (1) ES2328408T3 (fr)
MX (1) MX2008002180A (fr)
PL (1) PL1926712T3 (fr)
PT (1) PT1926712E (fr)
SI (1) SI1926712T1 (fr)
WO (1) WO2007028131A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619450C (fr) * 2005-09-01 2013-10-22 Eli Lilly And Company 2,3,4,5-tetrahydro-1h-benzo[d]azepines substituees par un heterocycle a liaison 6-n en tant qu'agonistes de recepteur 5-ht2c
DK1924560T3 (da) * 2005-09-01 2009-10-19 Lilly Co Eli 6-substituerede-2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C-receptoragonister
CA2619448C (fr) * 2005-09-01 2013-08-13 Eli Lilly And Company Utilisation de 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines comme agonistes des recepteurs 5-ht2c
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
CN101684096A (zh) * 2008-09-23 2010-03-31 中国科学院上海药物研究所 一类新型苯并氮杂卓类化合物及其制备方法和用途
JP5579262B2 (ja) * 2009-06-15 2014-08-27 武田薬品工業株式会社 ピラジノオキサゼピン誘導体
SG188361A1 (en) * 2010-09-01 2013-04-30 Arena Pharm Inc Non-hygroscopic salts of 5-ht2c agonists
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
CN103189358A (zh) * 2010-09-01 2013-07-03 艾尼纳制药公司 5-ht2c激动剂的快速溶解剂型
JP2013539470A (ja) * 2010-09-01 2013-10-24 アリーナ ファーマシューティカルズ， インコーポレイテッド ロルカセリンと光学活性な酸との塩
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
WO2015066344A1 (fr) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. Agonistes du récepteur 5-ht2c et compositions et procédés d'utilisation
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639748A (en) * 1991-08-05 1997-06-17 Smithkline Beecham Corporation 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity
WO2005019180A1 (fr) * 2003-08-11 2005-03-03 Eli Lilly And Company 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d]azepine utilisee comme agoniste du recepteur 5-ht2c
WO2005042491A1 (fr) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Derives de benzazepine et methodes de prophylaxie ou traitement de maladies associees au recepteur 5ht2c
WO2005082859A1 (fr) * 2004-02-25 2005-09-09 Eli Lilly And Company 2,3,4,5-tetrahydro-1h-benzo[d]azepines substitues en position 6 en tant qu'agonistes de recepteur 5-ht2c

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4265890A (en) * 1978-07-07 1981-05-05 Smithkline Corporation 6-Phenyl thio- and 6-cyclohexyl thio-2,3,4,5-tetrahydro-1H-3-benzazepines
EP0285287A3 (fr) 1987-03-23 1990-08-16 Smithkline Beecham Corporation Emploi de 3-benzazépines pour le traitement des troubles de la mobilité gastro-intestinale
US4985352A (en) * 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
GB9116824D0 (en) 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
WO1993004866A1 (fr) 1991-09-11 1993-03-18 Canon Kabushiki Kaisha Element de nettoyage ameliore pour tete de jet d'encre et dispositif a jet d'encre equipe d'un tel element de nettoyage
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
US5698766A (en) * 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
JP2002371059A (ja) * 2000-05-16 2002-12-26 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
EP1213017A3 (fr) 2000-12-05 2003-11-12 Akzo Nobel N.V. Utilisation d'un agoniste du récepteur 5-HT2C pour traiter les bouffées de chaleur
JPWO2002074746A1 (ja) * 2001-03-16 2004-07-08 山之内製薬株式会社 ベンゾアゼピン誘導体
DE60206762T2 (de) 2001-07-13 2006-07-13 Pharmacia & Upjohn Co. Llc, Kalamazoo Hexahydroazepino(4,5-g)indole und -indoline als 5-ht rezeptor-liganden
CA2468010A1 (fr) * 2001-11-28 2003-06-05 Pharmacia & Upjohn Company Composes therapeutiques
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
EP1636191A2 (fr) 2003-06-17 2006-03-22 Arena Pharmaceuticals, Inc. Processus de preparation de benzazepines pour le traitement des maladies associées avec le recepteur 5ht2c
CN1805938B (zh) * 2003-06-17 2010-06-16 艾尼纳制药公司 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物
US20070275949A1 (en) * 2003-10-22 2007-11-29 Arena Pharmaceuticals, Inc. Benzazepine Derivatives and Methods of Prophylaxis or Treatment of 5Ht2C Receptor Associated Diseases
NZ555981A (en) 2004-12-21 2011-01-28 Arena Pharm Inc Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride
EP1833473B1 (fr) 2004-12-23 2009-09-09 Arena Pharmaceuticals, Inc. Compositions renfermant un modulateur des recepteurs 5ht2c et procedes d'utilisation correspondants
DK1924560T3 (da) * 2005-09-01 2009-10-19 Lilly Co Eli 6-substituerede-2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C-receptoragonister
CA2619450C (fr) * 2005-09-01 2013-10-22 Eli Lilly And Company 2,3,4,5-tetrahydro-1h-benzo[d]azepines substituees par un heterocycle a liaison 6-n en tant qu'agonistes de recepteur 5-ht2c
CA2619448C (fr) * 2005-09-01 2013-08-13 Eli Lilly And Company Utilisation de 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines comme agonistes des recepteurs 5-ht2c

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639748A (en) * 1991-08-05 1997-06-17 Smithkline Beecham Corporation 6,9-disubstituted benzazepines having α-adrenoceptor blocking activity
WO2005019180A1 (fr) * 2003-08-11 2005-03-03 Eli Lilly And Company 6-(2,2,2-trifluoroethylamino)-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d]azepine utilisee comme agoniste du recepteur 5-ht2c
WO2005042491A1 (fr) * 2003-10-22 2005-05-12 Arena Pharmaceuticals, Inc. Derives de benzazepine et methodes de prophylaxie ou traitement de maladies associees au recepteur 5ht2c
WO2005082859A1 (fr) * 2004-02-25 2005-09-09 Eli Lilly And Company 2,3,4,5-tetrahydro-1h-benzo[d]azepines substitues en position 6 en tant qu'agonistes de recepteur 5-ht2c

Also Published As

Publication number Publication date
AU2006287160A1 (en) 2007-03-08
CY1110486T1 (el) 2015-04-29
EP1926712A1 (fr) 2008-06-04
CA2619287C (fr) 2013-10-22
CA2619287A1 (fr) 2007-03-08
US20080207897A1 (en) 2008-08-28
PT1926712E (pt) 2009-10-06
EP1926712B1 (fr) 2009-07-29
DK1926712T3 (da) 2009-11-09
BRPI0615033A2 (pt) 2011-04-26
PL1926712T3 (pl) 2009-12-31
ES2328408T3 (es) 2009-11-12
US8420631B2 (en) 2013-04-16
CN101253153A (zh) 2008-08-27
ATE437859T1 (de) 2009-08-15
JP2009507037A (ja) 2009-02-19
WO2007028131A1 (fr) 2007-03-08
JP5237810B2 (ja) 2013-07-17
DE602006008155D1 (de) 2009-09-10
MX2008002180A (es) 2008-04-22
SI1926712T1 (sl) 2010-01-29

Similar Documents

Publication Publication Date Title
AU2006287160B2 (en) 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
EP1924560B1 (fr) 2,3,4,5-tetrahydro-1h-benzo[d]azepines 6-substituees en tant qu'antagonistes du recepteur 5-ht2c
CA2619450C (fr) 2,3,4,5-tetrahydro-1h-benzo[d]azepines substituees par un heterocycle a liaison 6-n en tant qu'agonistes de recepteur 5-ht2c
EP1924561B1 (fr) 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines agonistes du recepteur 5-ht2c
EP2479168B1 (fr) 6-substitué 2,3,4,5-tetrahydro-1H-benzo [d] azépines comme agonistes du récepteur 5-HT2C
US20060264418A1 (en) 6-(2,2,2-Trifluoroethylamino-7-chloro-2,3,4,5-tetrahydro-1h-benzo[d] azephine as a 5-ht2c receptor agonist

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired